

HEPARIN SODIUM IN SODIUM CHLORIDE- heparin sodium in sodium chloride injection

B. Braun Medical Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION safely and effectively. See full prescribing information for HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION.

HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION, for intravenous use

Initial U.S. Approval: 1939

INDICATIONS AND USAGE

HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION at the concentration of 2 USP units/mL is an anticoagulant indicated for:

- Maintenance of catheter patency (1)

DOSAGE AND ADMINISTRATION

Although the rate of infusion of the 2 USP units/mL formulation is dependent upon the age, weight, clinical condition of the patient, and the procedure being employed, the recommended starting rate is 6 units per hour by intravenous infusion through an intravenous catheter to maintain catheter patency. (2.2)

DOSAGE FORMS AND STRENGTHS

- Heparin Sodium 1,000 USP units per 500 mL (2 USP units per mL) in 0.9% Sodium Chloride Injection (3)
- Heparin Sodium 2,000 USP units per 1,000 mL (2 USP units per mL) in 0.9% Sodium Chloride Injection (3)

CONTRAINDICATIONS

Heparin Sodium in Sodium Chloride Injection is contraindicated in patients with the following conditions: (4)

- Uncontrollable active bleeding state, except when this is due to disseminated intravascular coagulation (5.2)
- History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT) (5.3)
- With severe thrombocytopenia (5.3, 5.4)
- Known hypersensitivity to heparin or pork products (5.5, 6.1)

WARNINGS AND PRECAUTIONS

- Fatal Medication Errors: Confirm choice of correct strength prior to administration. (5.1)
- Hemorrhage: Fatal cases have occurred. Monitor for signs of bleeding and manage promptly. (5.2)
- HIT or HITT: Monitor for signs and symptoms and discontinue if indicative of HIT or HITT. (5.3)
- Thrombocytopenia: Monitor platelet count during therapy; discontinue heparin in HIT or HITT is suspected. (5.4)
- Hypersensitivity Reactions: Use in patients with prior reactions only in life-threatening situations. (5.5)
- Heparin Resistance: Increased resistance to heparin is frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer and in postsurgical patients. (5.6)
- Hyperkalemia: Measure plasma potassium in patients at risk of hyperkalemia before starting heparin therapy and periodically in all patients (5.7)
- Elevations of serum aminotransferases: Interpret elevation of these enzymes with caution. (5.8)
- Laboratory Tests: Periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy regardless of the route of administration. (5.9)

ADVERSE REACTIONS

Most common adverse reactions are: hemorrhage, thrombocytopenia, HIT or HITT, hypersensitivity reactions, heparin resistance, hyperkalemia, and elevations of aminotransferase levels. (6)

To report SUSPECTED ADVERSE REACTIONS, contact B. Braun Medical Inc. at 1-800-227-2862 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Drugs that interfere with platelet aggregation or drugs that counteract coagulation may induce

bleeding. (7)

----- **USE IN SPECIFIC POPULATIONS** -----

Geriatric Use: A higher incidence of bleeding has been reported in patients over 60 years of age, especially women. (5.2, 8.5)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Preparation for Administration
- 2.2 Maintenance of Catheter Patency

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Fatal Medication Errors
- 5.2 Hemorrhage
- 5.3 Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT)
- 5.4 Thrombocytopenia
- 5.5 Hypersensitivity Reactions
- 5.6 Heparin Resistance
- 5.7 Hyperkalemia
- 5.8 Elevations of Serum Aminotransferases
- 5.9 Laboratory Tests

6 ADVERSE REACTIONS

- 6.1 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Oral Anticoagulants
- 7.2 Platelet Inhibitors
- 7.3 Other Medications that May Interfere with Heparin

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Heparin Sodium in 0.9% Sodium Chloride Injection at the concentration of 2 USP units/mL is indicated as an anticoagulant to maintain catheter patency.

2 DOSAGE AND ADMINISTRATION

2.1 Preparation for Administration

Confirm the selection of the correct formulation and strength prior to administration of the drug.

This product should be administered by intravenous infusion only.

Do not use Heparin Sodium in 0.9% Sodium Chloride Injection as a “catheter lock flush” product.

Do not admix with other drugs.

Discard unused portion.

Do not use plastic containers in series connection.

This product should not be infused under pressure.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use only if solution is clear and container and seals are intact.

2.2 Maintenance of Catheter Patency

Although the rate of infusion of the 2 USP units/mL formulation is dependent upon the age, weight, clinical condition of the patient, and the procedure being employed, the recommended starting rate is 6 units per hour by intravenous infusion through an intravenous catheter to maintain catheter patency.

3 DOSAGE FORMS AND STRENGTHS

HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION is a sterile, single-dose, clear, nonpyrogenic solution available as:

- Heparin Sodium 1,000 USP units per 500 mL (2 USP units per mL) in 0.9% Sodium Chloride Injection.
- Heparin Sodium 2,000 USP units per 1,000 mL (2 USP units per mL) in 0.9% Sodium Chloride Injection.

4 CONTRAINDICATIONS

The use of HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION is contraindicated in patients with the following conditions:

- Uncontrollable active bleeding state except when this is due to disseminated intravascular coagulation [*see Warnings and Precautions (5.2)*]
- History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT) [*see Warnings and Precautions (5.3)*]
- Severe thrombocytopenia [*see Warnings and Precautions (5.3, 5.4)*]
- Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [*see Warnings and Precautions (5.5) and Adverse Reactions (6.1)*]

5 WARNINGS AND PRECAUTIONS

5.1 Fatal Medication Errors

Do not use this product as a “catheter lock flush” product. Heparin is supplied in various strengths. Fatal hemorrhages have occurred due to medication errors. Carefully examine all heparin products to confirm the correct container choice prior to administration of the drug.

5.2 Hemorrhage

Hemorrhage, including fatal events, has occurred in patients receiving HEPARIN SODIUM. Avoid using heparin in the presence of major bleeding, except when the benefits of heparin therapy outweigh the potential risks.

Hemorrhage can occur at virtually any site in patients receiving heparin. Adrenal hemorrhage (with resultant acute adrenal insufficiency), ovarian hemorrhage, and retroperitoneal hemorrhage have occurred during anticoagulant therapy with heparin [*see Adverse Reactions (6.1)*]. A higher incidence of bleeding has been reported in patients, particularly women, over 60 years of age [*see Clinical Pharmacology (12.3)*]. An unexplained fall in hematocrit or fall in blood pressure should lead to serious consideration of a hemorrhagic event.

Use heparin sodium with caution in disease states in which there is increased risk of hemorrhage, including:

- Cardiovascular — Subacute bacterial endocarditis. Severe hypertension.
- Surgical — During and immediately following (a) spinal tap or spinal anesthesia or (b) major surgery, especially involving the brain, spinal cord or eye.
- Hematologic — Conditions associated with increased bleeding tendencies, such as hemophilia, thrombocytopenia and some vascular purpuras.
- Patients with hereditary antithrombin III deficiency receiving concurrent antithrombin III therapy — The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency. To reduce the risk of bleeding, reduce the heparin dose during concomitant treatment with antithrombin III (human).
- Gastrointestinal — Ulcerative lesions and continuous tube drainage of the stomach or small intestine.
- Other — Menstruation, liver disease with impaired hemostasis.

5.3 Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT)

HIT is a serious immune-mediated reaction resulting from irreversible aggregation of platelets. HIT occurs in patients treated with heparin and is due to the development of antibodies to a platelet Factor 4-heparin complex that induce *in vivo* platelet aggregation. HIT may progress to the development of venous and arterial thromboses, a condition known as HITT. Thrombotic events may also be the initial presentation for HIT. These serious thromboembolic events include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, thrombus formation on a prosthetic cardiac valve, mesenteric thrombosis, renal arterial thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.

Once HIT or HITT is diagnosed or strongly suspected, discontinue all heparin sources (including heparin flushes) and use an alternative anticoagulant.

Immune-mediated HIT is diagnosed based on clinical findings supplemented by laboratory tests confirming the presence of antibodies to heparin, or platelet activation induced by heparin. Obtain platelet counts at baseline and periodically during heparin administration. A drop in platelet count greater than 50% from baseline is considered indicative of HIT. Platelet counts begin to fall 5 to 10 days after exposure to heparin in heparin-naïve individuals and reach a threshold by days 7 to 14. In contrast, “rapid onset” HIT can occur very quickly (within 24 hours following heparin initiation), especially in patients with a recent exposure to heparin (i.e., previous 3 months).

Thrombosis development shortly after documenting thrombocytopenia is a characteristic finding in almost half of all patients with HIT.

Monitor thrombocytopenia of any degree closely. If the platelet count falls below 100,000/mm³ or if recurrent thrombosis develops, promptly discontinue heparin, evaluate for HIT and HITT, and, if necessary, administer an alternative anticoagulant.

HIT or HITT can occur up to several weeks after the discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT or HITT.

5.4 Thrombocytopenia

Thrombocytopenia has been reported to occur in patients receiving heparin with a reported incidence of up to 30%. It can occur 2 to 20 days (average 5 to 9) following the onset of heparin therapy. Obtain platelet counts before and periodically during heparin therapy. Monitor thrombocytopenia of any degree closely. If the count falls below 100,000/mm³ or if recurrent thrombosis develops, promptly discontinue heparin, evaluate for HIT and HITT, and, if necessary, administer an alternative anticoagulant [*see Warnings and Precautions (5.3)*].

5.5 Hypersensitivity Reactions

Hypersensitivity reactions with chills, fever and urticaria as the most usual manifestations and also asthma, rhinitis, lacrimation, and anaphylactoid reactions have been reported. Patients with documented hypersensitivity to heparin should be given the drug only in clearly life-threatening situations. [*see Adverse Reactions (6.1)*].

Because Heparin Sodium in 0.9% Sodium Chloride Injection is derived from animal tissue, monitor for signs and symptoms of hypersensitivity when it is used in patients with a history of allergy to pork products.

5.6 Heparin Resistance

Increased resistance to heparin is frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer, in postsurgical patients, and patients with anti-thrombin deficiency. Consider measurement of anti-thrombin levels if heparin resistance is suspected. Monitor coagulation tests frequently in such patients. It may be necessary to adjust the dose of heparin based on coagulation test monitoring, such as anti-Factor Xa levels and/or partial thromboplastin time.

5.7 Hyperkalemia

Heparin can suppress adrenal secretion of aldosterone leading to hyperkalemia, particularly in patients with diabetes mellitus, chronic renal failure, pre-existing metabolic acidosis, a raised plasma potassium, or taking potassium sparing drugs. The risk of hyperkalemia appears to increase with duration of therapy but is usually reversible upon discontinuation of heparin.

Measure plasma potassium in patients at risk of hyperkalemia before starting heparin therapy and periodically in all patients treated for more than 5 days or earlier as deemed fit by the clinician.

5.8 Elevations of Serum Aminotransferases

Significant elevations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels have occurred in patients who have received heparin. Elevation of these enzymes in patients receiving heparin should be interpreted with caution. These elevations typically resolve upon heparin discontinuation.

5.9 Laboratory Tests

Periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy, regardless of the route of administration.

6 ADVERSE REACTIONS

The following serious adverse reactions are described elsewhere in the labeling:

- Hemorrhage [*see Warnings and Precautions (5.2)*]
- Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia and Thrombosis [*see Warnings and Precautions (5.3)*]
- Thrombocytopenia [*see Warnings and Precautions (5.4)*]
- Hypersensitivity Reactions [*see Warnings and Precautions (5.5)*]
- Heparin Resistance [*see Warnings and Precautions (5.6)*]
- Hyperkalemia [*see Warnings and Precautions (5.7)*]
- Elevations of Serum Aminotransferases [*see Warnings and Precautions (5.8)*]

6.1 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of heparin sodium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

- **Hemorrhage** - Hemorrhage is the chief complication that may result from heparin therapy [see *Warnings and Precautions (5.2)*]. An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing the drug [see *Overdosage (10)*]. Gastrointestinal or urinary tract bleeding during anticoagulant therapy may indicate the presence of an underlying occult lesion. Bleeding can occur at any site but certain specific hemorrhagic complications may be difficult to detect:
 - Adrenal hemorrhage, with resultant acute adrenal insufficiency, has occurred with heparin therapy, including fatal cases.
 - Ovarian (corpus luteum) hemorrhage developed in a number of women of reproductive age receiving short- or long-term anticoagulant therapy.
 - Retroperitoneal hemorrhage.
- **Vascular Disorders** - Contusion, Vasospastic reactions (including episodes of painful, ischemic, and cyanosed limbs).
- **HIT and HITT, including delayed onset cases, and Thrombocytopenia** - [see *Warnings and Precautions (5.3 and 5.4)*]
- **Histamine-like reactions** - Such reactions have been observed at the site of injections. Necrosis of the skin has been reported at the site of subcutaneous injection of heparin, occasionally requiring skin grafting.
- **Hypersensitivity** - Generalized hypersensitivity reactions have been reported with chills, fever, and urticaria as the most usual manifestations, and asthma, rhinitis, lacrimation, headache, nausea and vomiting, and anaphylactoid reactions, including shock, occurring more rarely. Itching and burning, especially on the plantar site of the feet, may occur [see *Warnings and Precautions (5.5)*].
- **Musculoskeletal, Connective Tissue and Bone Disorders** - Osteoporosis with long-term administration of heparin.
- **Metabolism and Nutrition Disorders** - Hyperkalemia.
- **General Disorders and Administration Site Conditions** - Erythema, mild pain, ulceration.
- **Elevations of serum aminotransferases** - Significant elevations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels have occurred in patients who have received heparin.
- **Others** - Cutaneous necrosis after systemic administration, delayed transient alopecia, priapism, and rebound hyperlipemia on discontinuation of heparin sodium have also been reported.

7 DRUG INTERACTIONS

7.1 Oral Anticoagulants

Heparin sodium may prolong the one-stage prothrombin time. Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.

7.2 Platelet Inhibitors

Drugs such as NSAIDS (including acetylsalicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. To reduce the risk of bleeding, a reduction in the dose of antiplatelet agent or heparin is recommended.

7.3 Other Medications that May Interfere with Heparin

Digitalis, tetracyclines, nicotine or antihistamines may partially counteract the anticoagulant action of heparin sodium. Intravenous nitroglycerin administered to heparinized patients may result in a decrease of the partial thromboplastin time with subsequent rebound effect upon discontinuation of nitroglycerin. Careful monitoring of partial thromboplastin time and adjustment of heparin dosage are recommended during coadministration of heparin and intravenous nitroglycerin.

Antithrombin III (human) – The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency. To reduce the risk of bleeding, a reduced dosage of heparin is recommended during treatment with antithrombin III (human).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

In published reports, heparin exposure during pregnancy did not show evidence of an increased risk of adverse maternal or fetal outcomes in humans. No teratogenicity was observed in animal reproduction studies with administration of heparin sodium to pregnant rats and rabbits during organogenesis at doses, approximately 2777 times the recommended human dose (MRHD) for maintenance of catheter patency of heparin [see *Data*]. In pregnant animals, doses up to 2777 times higher than the human daily dose of heparin resulted in increased resorptions. Consider the benefits and risks of HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION to a pregnant woman and possible risks to the fetus when prescribing HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Human Data

The maternal and fetal outcomes associated with uses of heparin via various dosing methods and administration routes during pregnancy have been investigated in

numerous studies. These studies generally reported normal deliveries with no maternal or fetal bleeding and no other complications.

Animal Data

In a published study conducted in rats and rabbits, pregnant animals received heparin intravenously during organogenesis at a dose of 10,000 USP units/kg/day, approximately 2777 times the human daily dose. The number of early resorptions increased in both species. There was no evidence of teratogenic effects.

8.2 Lactation

Risk Summary

There is no information regarding the presence of HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION in human milk, the effects on the breastfed infant, or the effects on milk production. Due to its large molecular weight, heparin is not likely to be excreted in human milk, and any heparin in milk would not be orally absorbed by a nursing infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION and any potential adverse effects on the breastfed infant from HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION or from the underlying maternal condition [*see Use in Specific Populations (8.4)*].

8.4 Pediatric Use

There are no adequate and well controlled studies on heparin use in pediatric patients.

8.5 Geriatric Use

There are limited adequate and well-controlled studies in patients 65 years and older. However, a higher incidence of bleeding has been reported in patients over 60 years of age, especially women [*see Warnings and Precautions (5.2)*].

10 OVERDOSAGE

An overdose requires immediate medical attention and treatment.

Symptoms

Bleeding is the chief sign of heparin overdose. Easy bruising, petechial formations, nosebleeds, blood in urine or tarry stools may be the first signs or symptoms of a heparin overdose. In the event of symptomatic heparin overdose, consider stopping heparin infusion.

Treatment

Neutralization of heparin effect:

When clinical circumstances (bleeding) require reversal of heparinization, protamine sulfate (1% solution) by slow infusion will neutralize heparin sodium. **No more than 50 mg** should be administered, **very slowly**, in any 10 minute period. Each mg of protamine sulfate neutralizes approximately 100 USP Heparin units. The amount of protamine required decreases over time as heparin is metabolized. Although the

metabolism of heparin is complex, it may, for the purpose of choosing a protamine dose, be assumed to have a half-life of about 30 minutes after intravenous injection.

Ideally, the dose required to neutralize the action of heparin should be guided by blood coagulation tests or calculated from a protamine neutralization test.

Because fatal reactions often resembling anaphylaxis have been reported, protamine sulfate should be given only when resuscitation techniques and treatment of anaphylactoid shock are readily available.


For additional information, consult the prescribing information for Protamine Sulfate Injection, USP.

Blood or plasma transfusions may be necessary; these dilute but do not neutralize heparin.

11 DESCRIPTION

Heparin is a heterogenous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans having anticoagulant properties. It is composed of polymers of alternating derivations of alpha-L-iduronic acid 2-sulfate (1), 2-deoxy-2-sulfamino-alpha-D-glucose 6-sulfate (2), beta-D-glucuronic acid (3), 2-acetamido-2-deoxy-alpha-D-glucose (4), and alpha-L-iduronic acid (5).

Structure of Heparin Sodium (representative subunits):



Heparin Sodium in 0.9% Sodium Chloride Injection is a sterile, single-dose, clear, nonpyrogenic solution prepared from Heparin Sodium USP (derived from porcine intestinal mucosa and standardized for use as an anticoagulant) in 0.9% Sodium Chloride Injection. It is to be administered by intravenous injection. The potency is determined by a biological assay using a USP reference standard based on units of heparin activity per milligram.

Each 100 mL contains 200 USP Units Heparin Sodium, 0.43 g Dibasic Sodium Phosphate•7H₂O USP and 0.037 g Citric Acid Anhydrous USP as a buffer system, 0.9 g Sodium Chloride USP, and Water for Injection USP qs.

pH: 7.0 (6.8-7.2); Calculated Osmolarity: 360 mOsmol/liter

Concentration of Electrolytes (mEq/liter): Sodium 186; Chloride 154; Phosphate (HPO₄²⁻) 32; Citrate 6

The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

The plastic container is not made with natural rubber latex, PVC or DEHP.

The closure system has two ports; the one for the administration set has a tamper evident plastic protector.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots.

12.2 Pharmacodynamics

Various times (activated clotting time, activated partial thromboplastin time, prothrombin time, whole blood clotting time) are prolonged by full therapeutic doses of heparin; in most cases, they are not measurably affected by low doses of heparin. Bleeding time is usually unaffected by heparin.

12.3 Pharmacokinetics

Absorption

Heparin is not absorbed through the gastrointestinal tract and therefore administered via parenteral route. Peak plasma concentration and the onset of action are achieved immediately after intravenous administration.

Distribution

Heparin is highly bound to antithrombin, fibrinogens, globulins, serum proteases and lipoproteins. The volume of distribution is 0.07 L/kg.

Elimination

Metabolism

Heparin does not undergo enzymatic degradation.

Excretion

Heparin is mainly cleared from the circulation by liver and reticuloendothelial cells mediated uptake into extravascular space. Heparin undergoes biphasic clearance, a)

rapid saturable clearance (zero order process due to binding to proteins, endothelial cells and macrophages) and b) slower first order elimination. Low doses of heparin are cleared mostly by a saturable, rapid, zero-order process. Slower first order elimination usually occurs with very high doses of heparin and is dependent on renal function. The plasma half-life is dose-dependent, and it ranges from 0.5 to 2 h.

Specific Populations

Geriatric Patients

Patients over 60 years of age, following similar doses of heparin, may have higher plasma levels of heparin and longer activated partial thromboplastin times (APTTs) compared with patients under 60 years of age [see *Use in Specific Populations (8.5)*].

Renal and Hepatic Impairment

The rate of clearance of unfractionated heparin may be decreased in patients with renal or hepatic impairment. Patients with renal or hepatic impairment, following similar doses of heparin may have higher plasma levels of heparin compared with patient with normal renal and hepatic function [see *Warnings and Precautions (5.2)*].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals to evaluate the carcinogenic potential, reproduction studies in animals to determine effects on fertility of males and females, and studies to determine mutagenic potential have not been conducted.

16 HOW SUPPLIED/STORAGE AND HANDLING

Heparin Sodium in 0.9% Sodium Chloride Injection is a clear solution and is supplied sterile and nonpyrogenic in single-dose EXCEL[®] Containers. The 1,000 mL containers are packaged 12 per case and 500 mL containers are packaged 24 per case.

<u>NDC</u>	<u>REF</u>	<u>Concentration</u>	<u>Size</u>
0264-9872-10	P8721	Heparin Sodium 1,000 USP units per 500 mL (2 USP units per mL) in 0.9% Sodium Chloride Injection	500 mL
0264-9872-00	P8720	Heparin Sodium 2,000 USP units per 1,000 mL (2 USP units per mL) in 0.9% Sodium Chloride Injection	1,000 mL

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.]

17 PATIENT COUNSELING INFORMATION

Hemorrhage

Inform patients that it may take them longer than usual to stop bleeding, that they may

bruise and/or bleed more easily when they are treated with heparin, and that they should report any unusual bleeding or bruising to their physician. Hemorrhage can occur at virtually any site in patients receiving heparin. Fatal hemorrhages have occurred [see *Warnings and Precautions (5.2)*].

Prior to Surgery

Advise patients to inform physicians and dentists that they are receiving heparin before any surgery is scheduled [see *Warnings and Precautions (5.2)*].

Heparin-Induced Thrombocytopenia

Inform patients of the risk of heparin-induced thrombocytopenia (HIT). HIT may progress to the development of venous and arterial thromboses, a condition known as heparin-induced thrombocytopenia and thrombosis (HITT). HIT or HITT can occur up to several weeks after the discontinuation of heparin therapy [see *Warnings and Precautions (5.3 and 5.4)*].

Hypersensitivity

Inform patients that generalized hypersensitivity reactions have been reported. Necrosis of the skin has been reported at the site of subcutaneous injection of heparin [see *Warnings and Precautions (5.5), Adverse Reactions (6.1)*].

Other Medications

Because of the risk of hemorrhage, advise patients to inform their physicians and dentists of all medications they are taking, including non-prescription medications, and before starting any new medication [see *Drug Interactions (7)*].

Rx only

EXCEL is a registered trademark of B. Braun Medical Inc.

B. Braun Medical Inc.

Bethlehem, PA 18018-3524 USA

1-800-227-2862

Y36-003-067 LD-240-9

PRINCIPAL DISPLAY PANEL - 1000 mL Container Label

NDC 0264-9872-00

HEPARIN SODIUM in
0.9% Sodium Chloride Injection
2,000 USP units per 1000 mL
(2 USP units per mL)

LD-756-1 Y94-003-481

For Intravenous Use Only

**Each 100 mL contains: Heparin Sodium USP
(porcine intestinal mucosa) 200 USP Heparin units;**

Sodium Chloride USP 0.9 g;
Dibasic Sodium Phosphate•7H₂O USP 0.43 g;
Citric Acid Anhydrous USP 0.037 g;
Water for Injection USP qs

Electrolytes (mEq/liter): Sodium 186; Chloride 154;
Phosphate (HPO₄⁼) 32; Citrate 6

WARNING: Do not admix with other drugs.

Sterile. Single dose container. Discard unused portion.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing. Recommended Dosage: see Prescribing Information. Do not remove overwrap until ready for use.

Not made with natural rubber latex, PVC or DEHP.

EXCEL is a registered trademark of B. Braun Medical Inc.

1000 mL EXCEL[®] CONTAINER

Rx only

REF P8720



B. Braun Medical Inc.

Bethlehem, PA 18018-3524 USA

1-800-227-2862

Prepared in USA. API from Spain.

Y94-003-480 LD-755-1

EXP

LOT



NDC 0264-9872-00

HEPARIN SODIUM in 0.9% Sodium Chloride Injection

LD-755-1 754-003-481

2,000 USP units per 1000 mL
(2 USP units per mL)

For Intravenous Use Only

Each 100 mL contains: Heparin Sodium USP
(porcine intestinal mucosa) 200 USP Heparin units;
Sodium Chloride USP 0.9 g;
Dibasic Sodium Phosphate•7H₂O USP 0.43 g;
Citric Acid Anhydrous USP 0.037 g;
Water for Injection USP qs

Electrolytes (mEq/liter): Sodium 186; Chloride 154;
Phosphate (HPO₄) 32; Citrate 6

WARNING: Do not admix with other drugs.

Sterile. Single dose container. Discard unused portion.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing. Recommended Dosage: see Prescribing Information. Do not remove overwrap until ready for use.

Not made with natural rubber latex, PVC or DEHP.

EXCEL is a registered trademark of B. Braun Medical Inc.

1000 mL
EXCEL® CONTAINER

Rx only
REF P8720

BARCODE

BARCODE

Y94-003-480 LD-755-1



B | BRAUN

B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862
Prepared in USA. API from Spain

-0-
-1-
-2-
-3-
-4-
-5-
-6-
-7-
-8-
-9-



EXP

LOT

PRINCIPAL DISPLAY PANEL - 500 mL Container Label

NDC 0264-9872-10

HEPARIN SODIUM in
0.9% Sodium Chloride Injection
1,000 USP units per 500 mL
(2 USP units per mL)

LD-312-7 Y94-003-483

For Intravenous Use Only

Each 100 mL contains: Heparin Sodium USP
(porcine intestinal mucosa) 200 USP Heparin units;
Sodium Chloride USP 0.9 g;
Dibasic Sodium Phosphate•7H₂O USP 0.43 g;
Citric Acid Anhydrous USP 0.037 g;
Water for Injection USP qs

Electrolytes (mEq/liter): Sodium 186; Chloride 154;
Phosphate (HPO₄⁼) 32; Citrate 6

WARNING: Do not admix with other drugs.

Sterile. Single dose container. Discard unused portion.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing. Recommended Dosage: see Prescribing Information. Do not remove overwrap until ready for use.

Not made with natural rubber latex, PVC or DEHP.

EXCEL is a registered trademark of B. Braun Medical Inc.

500 mL EXCEL® CONTAINER

Rx only

REF P8721



B. Braun Medical Inc.

Bethlehem, PA 18018-3524 USA

1-800-227-2862

Prepared in USA. API from Spain.

Y94-003-482 LD-311-6

EXP

LOT



NDC 0264-9872-10

HEPARIN SODIUM in **1,000**
0.9% Sodium Chloride Injection **500 mL**
(2 USP units per mL)

LD-311-6 Y94-003-482

For Intravenous Use Only

Each 100 mL contains: **Heparin Sodium USP** (porcine intestinal mucosa)
200 USP Heparin units; **Sodium Chloride USP** 0.9 g;
Dibasic Sodium Phosphate•7H₂O USP 0.43 g; **Citric Acid Anhydrous USP** 0.037 g;
Water for Injection USP qs

Electrolytes (mEq/liter): **Sodium** 186; **Chloride** 154;
Phosphate (HPO₄²⁻) 32; **Citrate** 6

WARNING: Do not admix with other drugs.

Sterile. Single dose container. Discard unused portion.

Store at 20°C to 25°C (68°F to 77°F). Excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] Avoid excessive heat. Protect from freezing. Recommended Dosage: see Prescribing Information. Do not remove overwrap until ready for use.

Not made with natural rubber latex, PVC or DEHP.

500 mL
EXCEL® CONTAINER

Rx only **REF** P8721

2D
CODE

BARCODE

BARCODE

Y94-003-482 LD-311-6



EXCEL is a registered trademark of B. Braun Medical Inc.

B | BRAUN

B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862
Prepared in USA. API from Spain.

EXP

LOT

-0-
-1-
-2-
-3-
-4-

HEPARIN SODIUM IN SODIUM CHLORIDE

heparin sodium in sodium chloride injection

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0264-9872
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
HEPARIN SODIUM (UNII: ZZ45AB24CA) (HEPARIN - UNII:T2410KM04A)	HEPARIN	200 [USP'U] in 100 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	
SODIUM CHLORIDE (UNII: 451W47IQ8X)	0.9 g in 100 mL
SODIUM PHOSPHATE, DIBASIC (UNII: GR686LBA74)	0.43 g in 100 mL
ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)	0.037 g in 100 mL

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0264-9872-10	24 in 1 CASE	07/20/1992	
1		500 mL in 1 CONTAINER; Type 0: Not a Combination Product		
2	NDC:0264-9872-00	12 in 1 CASE	12/15/2023	
2		1000 mL in 1 CONTAINER; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA019953	07/20/1992	

Labeler - B. Braun Medical Inc. (002397347)

Revised: 12/2023

B. Braun Medical Inc.